Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2014, Article ID 179705, 10 pages
http://dx.doi.org/10.1155/2014/179705
Research Article

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

1Department of Nephrology, Charité, Medical University, 10117 Berlin, Germany
2Department of Nephrology and Transplantation Medicine, Westpfalz Hospital, 67655 Kaiserslautern, Germany
3Nephrology Center of Lower Saxony and Transplant Center, Vogelsang 105, 34346 Hann. Münden, Germany

Received 17 January 2014; Revised 24 March 2014; Accepted 24 March 2014; Published 4 May 2014

Academic Editor: Bruce Kaplan

Copyright © 2014 Klemens Budde et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Poesen, B. Bammens, K. Claes et al., “Prevalence and determinants of anemia in the immediate postkidney transplant period,” Transplant International, vol. 24, no. 12, pp. 1208–1215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Erslev and A. Besarab, “Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure,” Kidney International, vol. 51, no. 3, pp. 622–630, 1997. View at Google Scholar · View at Scopus
  3. J. M. Yabu and W. C. Winkelmayer, “Posttransplantation anemia: mechanisms and management,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 7, pp. 1794–1801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Shah, S. Al-Khoury, B. Afzali et al., “Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors,” Transplantation, vol. 81, no. 8, pp. 1112–1118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Joist, D. C. Brennan, and D. W. Coyne, “Anemia in the kidney-transplant patient,” Advances in Chronic Kidney Disease, vol. 13, no. 1, pp. 4–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Z. Molnar, I. Mucsi, I. C. Macdougall et al., “Prevalence and management of anaemia in renal transplant recipients: data from ten European centres,” Nephron Clinical Practice, vol. 117, no. 2, pp. c127–c134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Z. Molnar, M. Novak, C. Ambrus et al., “Anemia in kidney transplanted patients,” Clinical Transplantation, vol. 19, no. 6, pp. 825–833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Turkowski-Duhem, N. Kamar, O. Cointault et al., “Predictive factors of anemia within the first year post renal transplant,” Transplantation, vol. 80, no. 7, pp. 903–909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Kolonko, J. Pinocy-Mańdok, M. Kocierz et al., “Anemia and erythrocytosis after kidney transplantation: a 5-year graft function and survival analysis,” Transplantation Proceedings, vol. 41, no. 8, pp. 3046–3051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Fishbane, “Anemia and cardiovascular risk in the patient with kidney disease,” Heart Failure Clinics, vol. 4, no. 4, pp. 401–410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Thorp, E. S. Johnson, X. Yang, A. F. Petrik, R. Platt, and D. H. Smith, “Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease,” Nephrology, vol. 14, no. 2, pp. 240–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. P. Kovesdy, B. K. Trivedi, K. Kalantar-Zadeh, and J. E. Anderson, “Association of anemia with outcomes in men with moderate and severe chronic kidney disease,” Kidney International, vol. 69, no. 3, pp. 560–564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. C. Dowling, “Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview,” American Journal of Health-System Pharmacy, vol. 64, no. 13, supplement 8, pp. S3–S7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Kamar, L. Rostaing, S. Ignace, and E. Villar, “Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis,” Clinical Transplantation, vol. 26, no. 3, pp. 461–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. L. G. de Andrade, J. M. Abrão, and M. F. Carvalho, “Anemia at one year is an independent risk factor of graft survival,” International Urology and Nephrology, vol. 44, no. 1, pp. 263–268, 2012. View at Google Scholar
  16. D. Chhabra, M. Grafals, A. I. Skaro, M. Parker, and L. Gallon, “Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 4, pp. 1168–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Z. Molnar, M. Czira, C. Ambrus et al., “Anemia is associated with mortality in kidney-transplanted patients—a prospective cohort study,” American Journal of Transplantation, vol. 7, no. 4, pp. 818–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Djamali, Y. T. Becker, W. D. Simmons, C. A. Johnson, N. Premasathian, and B. N. Becker, “Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients,” Transplantation, vol. 76, no. 5, pp. 816–820, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. W. C. Winkelmayer, A. Chandraker, M. Alan Brookhart, R. Kramar, and G. Sunder-Plassmann, “A prospective study of anaemia and long-term outcomes in kidney transplant recipients,” Nephrology Dialysis Transplantation, vol. 21, no. 12, pp. 3559–3566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Vanrenterghem, C. Ponticelli, J. M. Morales et al., “Prevalence and management of anemia in renal transplant recipients: a European survey,” American Journal of Transplantation, vol. 3, no. 7, pp. 835–845, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Heinze, A. Kainz, W. H. Hörl, and R. Oberbauer, “Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study,” British Medical Journal, vol. 339, article b4018, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Pfeffer, E. A. Burdmann, C.-Y. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. B. Drüeke, F. Locatelli, N. Clyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. A. van Loo, R. Vanholder, P. Bernaert, J. de Roose, and N. Lameire, “Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study,” Nephrology Dialysis Transplantation, vol. 11, no. 9, pp. 1815–1821, 1996. View at Google Scholar · View at Scopus
  26. W. van Biesen, R. Vanholder, N. Veys, F. Verbeke, and N. Lameire, “Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation,” Transplantation, vol. 79, no. 3, pp. 367–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. D. Bloom, P. Bolin, S. R. Gandra, D. Scarlata, and J. Petersen, “Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the strata study,” Transplantation Proceedings, vol. 43, no. 5, pp. 1593–1600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Ribes, N. Kamar, J. Guitard, L. Esposito, and L. Rostaing, “Darbepoetin-alfa in renal-transplant patients: an observational monocentric study,” Clinical Nephrology, vol. 69, no. 2, pp. 102–106, 2008. View at Google Scholar · View at Scopus
  29. L. M. McDevitt, L. D. Smith, K. T. Somerville, J. L. Corbett, and F. S. Shihab, “A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation,” American Journal of Transplantation, vol. 5, no. 8, pp. 1948–1956, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Muirhead, D. C. Cattran, J. Zaltzman et al., “Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction,” Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 1216–1222, 1994. View at Google Scholar · View at Scopus
  31. National Kidney Foundation, “KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease,” American Journal of Kidney Diseases, vol. 47, no. 5, supplement 3, pp. S1–S146, 2006. View at Google Scholar
  32. I. C. Macdougall, R. Robson, S. Opatrná et al., “Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1211–1215, 2006. View at Google Scholar
  33. F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek, and R. Vanholder, “Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP),” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 348–354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Canaud, G. Mingardi, J. Braun et al., “Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study,” Nephrology Dialysis Transplantation, vol. 23, no. 11, pp. 3654–3661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. I. C. Macdougall, R. Walker, R. Provenzano et al., “C.E.R.A corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 337–347, 2008. View at Publisher · View at Google Scholar
  36. E. D. Poggio, X. Wang, D. M. Weinstein et al., “Assessing glomerular filtration rate by estimation equations in kidney transplant recipients,” American Journal of Transplantation, vol. 6, no. 1, pp. 100–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Weinreich, F. Leistikow, H.-G. Hartmann et al., “Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients,” Hemodialysis International, vol. 16, no. 1, pp. 11–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Koch, W. Treiber, and D. Fliser, “Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study,” Clinical Drug Investigation, vol. 33, no. 10, pp. 699–706, 2013. View at Google Scholar
  39. S. Fishbane and J. S. Berns, “Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin,” Kidney International, vol. 68, no. 3, pp. 1337–1343, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. K. van der Putten, F. H. van der Baan, H. Schellekens, and C. A. J. M. Gaillard, “Hemoglobin variability in patients with chronic kidney disease in the Netherlands,” International Journal of Artificial Organs, vol. 32, no. 11, pp. 787–793, 2009. View at Google Scholar · View at Scopus
  41. V. Agrawal, S. Mukherjee, R. Kosuri, and F. Dumler, “Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience,” American Journal of Therapeutics, vol. 17, no. 5, pp. 469–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. N. W. Levin, S. Fishbane, F. V. Cañedo et al., “Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA),” The Lancet, vol. 370, no. 9596, pp. 1415–1421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Sulowicz, F. Locatelli, J.-P. Ryckelynck et al., “Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 637–646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Spinowitz, D. W. Coyne, C. E. Lok et al., “C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks,” American Journal of Nephrology, vol. 28, no. 2, pp. 280–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. I. Sánchez-Fructuoso, J. C. Ruiz, J. V. Torregrosa et al., “Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study,” Advances in Therapy, vol. 29, no. 11, pp. 979–991, 2012. View at Publisher · View at Google Scholar
  46. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO clinical practice guideline for the care of kidney transplant recipients,” American Journal of Transplantation, vol. 9, supplement 3, pp. S1–S155, 2009. View at Google Scholar
  47. S. J. Chadban, L. Baines, K. Polkinghorne et al., “Anemia after kidney transplantation is not completely explained by reduced kidney function,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 301–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Z. Molnar, M. E. Czira, A. Rudas et al., “Association between the malnutrition-inflammation score and post-transplant anaemia,” Nephrology Dialysis Transplantation, vol. 26, no. 6, pp. 2000–2006, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Fishbane, D. J. Cohen, D. W. Coyne, A. Djamali, A. K. Singh, and J. B. Wish, “Posttransplant anemia: the role of sirolimus,” Kidney International, vol. 76, no. 4, pp. 376–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Ekberg, C. Bernasconi, J. Nöldeke et al., “Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 2004–2010, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. C. Webster, V. W. S. Lee, J. R. Chapman, and J. C. Craig, “Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials,” Transplantation, vol. 81, no. 9, pp. 1234–1248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. D. R. J. Kuypers, H. de Jonge, M. Naesens et al., “Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients,” Clinical Therapeutics, vol. 30, no. 4, pp. 673–683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. “Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group,” Transplantation, vol. 68, no. 3, pp. 391–396, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Friend, G. Russ, R. Oberbauer et al., “Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function,” Transplant International, vol. 20, no. 9, pp. 754–760, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. A. Szczech, H. X. Barnhart, J. K. Inrig et al., “Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes,” Kidney International, vol. 74, no. 6, pp. 791–798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. D. Solomon, H. Uno, E. F. Lewis et al., “Erythropoietic response and outcomes in kidney disease and type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1146–1155, 2010. View at Google Scholar
  57. Kidney Disease Improving Global Outcomes (KDIGO), “Clinical practice guideline for anemia in chronic kidney disease,” Kidney International Supplements, vol. 2, no. 4, pp. 292–298, 2012. View at Google Scholar
  58. F. Locatelli, G. Villa, A. L. M. de Francisco et al., “Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration,” Current Medical Research and Opinion, vol. 23, no. 5, pp. 969–979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. S. D. Roger, F. Locatelli, R. P. Woitas et al., “C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis,” Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 3980–3986, 2011. View at Publisher · View at Google Scholar · View at Scopus